<DOC>
	<DOCNO>NCT00316706</DOCNO>
	<brief_summary>This protocol post deal objective &amp; outcome measure extension phase Month 48 . The objective extension study evaluate long-term immunogenicity HPV 16/18 L1 VLP AS04 vaccine ( subject HPV Vaccine Group ) enzyme-linked immunosorbent assay ( ELISA ) . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT00196924 ) . The long-term follow-up study blind primary study unblinded open visit subsequent unblinding primary study HPV-013 ( NCT00196924 ) . During open phase , subject receive HPV-16/18 VLP/AS04 vaccine primary study continue participation follow-up study Month 48 . Subjects Control group ( HavrixÂ® ) attend one visit last study visit . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Human Papilloma Virus ( HPV ) Vaccine Trial Young Adolescent Women With GlaxoSmithKline Biologicals ' ( GSK Bio ) HPV-16/18 Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A female enrol immunological subset 580299013 study , receive three dos vaccine/control accord treatment allocation complete 580299013 study . Written inform assent obtain subject write informed consent obtain parent legally acceptable representative subject . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Use investigational nonregistered product ( drug vaccine ) plan use study period . Chronic administration immunosuppressant immunemodifying drug occur less 3 month prior blood sampling . Administration immunoglobulins and/or blood product within 3 month precede blood sampling .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Prophylaxis HPV-16/18 infection cervical neoplasia</keyword>
</DOC>